Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Clinical relevance of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma who underwent surgery following neoadjuvant modified FOLFIRINOX.
Authors
So Heun Lee
Asan Medical Center, Seoul, South Korea
So Heun Lee , Changhoon Yoo , Sora Kang , Heung-Moon Chang , Jae Ho Jeong , Kyu-Pyo Kim , Baek-Yeol Ryoo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.546
Abstract #
546
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.
First Author: Choong-kun Lee
Poster
2024 ASCO Annual Meeting
Neoadjuvant fractionated versus hypofractionated chemoradiotherapy in resectable and borderline resectable pancreatic cancer.
First Author: Darren Lee
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Analysis of survival outcomes in patients with pancreatic cancer who underwent upfront surgery.
First Author: Jae Hyup Jung
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A randomized, multi-center phase III trial of adjuvant chemotherapy with gemcitabine and capecitabine (GemCap) compared to capecitabine (Cap) alone in curatively resected biliary tract cancer (BilGemCap Study): KCSG HB20-14.
First Author: Joon Oh Park